IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 306 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $29,727,629 | +181.4% | 655,371 | +154.5% | 0.03% | +188.9% |
Q2 2023 | $10,564,158 | +4.7% | 257,474 | -8.8% | 0.01% | 0.0% |
Q1 2023 | $10,090,331 | -19.0% | 282,326 | -14.4% | 0.01% | -18.2% |
Q4 2022 | $12,457,943 | -13.0% | 329,837 | +1.9% | 0.01% | -15.4% |
Q3 2022 | $14,312,000 | +36.9% | 323,586 | +14.6% | 0.01% | +30.0% |
Q2 2022 | $10,454,000 | -4.3% | 282,382 | -4.2% | 0.01% | +25.0% |
Q1 2022 | $10,920,000 | +26.2% | 294,815 | +3.7% | 0.01% | +33.3% |
Q4 2021 | $8,655,000 | -10.4% | 284,424 | -1.3% | 0.01% | -14.3% |
Q3 2021 | $9,664,000 | -24.5% | 288,128 | -10.2% | 0.01% | -30.0% |
Q2 2021 | $12,792,000 | -10.1% | 320,680 | +1.3% | 0.01% | -9.1% |
Q1 2021 | $14,233,000 | -16.3% | 316,577 | +5.2% | 0.01% | -15.4% |
Q4 2020 | $17,008,000 | +20.3% | 300,806 | +0.9% | 0.01% | 0.0% |
Q3 2020 | $14,139,000 | -17.5% | 297,983 | +2.5% | 0.01% | -23.5% |
Q2 2020 | $17,138,000 | +26.5% | 290,676 | +1.4% | 0.02% | +6.2% |
Q1 2020 | $13,548,000 | -25.9% | 286,553 | -5.3% | 0.02% | -5.9% |
Q4 2019 | $18,283,000 | +4.7% | 302,653 | +3.9% | 0.02% | 0.0% |
Q3 2019 | $17,456,000 | +25.0% | 291,371 | +34.1% | 0.02% | +6.2% |
Q2 2019 | $13,969,000 | -18.2% | 217,356 | +3.3% | 0.02% | -23.8% |
Q1 2019 | $17,079,000 | +67.9% | 210,408 | +11.8% | 0.02% | +50.0% |
Q4 2018 | $10,170,000 | -0.0% | 188,123 | -4.6% | 0.01% | +7.7% |
Q3 2018 | $10,172,000 | +15.2% | 197,200 | -6.9% | 0.01% | +8.3% |
Q2 2018 | $8,830,000 | -21.2% | 211,900 | -16.6% | 0.01% | -25.0% |
Q1 2018 | $11,201,000 | -16.4% | 254,100 | -4.6% | 0.02% | -11.1% |
Q4 2017 | $13,395,000 | +18.5% | 266,300 | +19.5% | 0.02% | +5.9% |
Q3 2017 | $11,301,000 | +1.3% | 222,900 | +1.6% | 0.02% | -5.6% |
Q2 2017 | $11,156,000 | +29.4% | 219,300 | +2.2% | 0.02% | +28.6% |
Q1 2017 | $8,623,000 | -19.4% | 214,500 | -4.2% | 0.01% | -22.2% |
Q4 2016 | $10,704,000 | +30.5% | 223,800 | 0.0% | 0.02% | +38.5% |
Q3 2016 | $8,200,000 | +47.2% | 223,800 | -6.4% | 0.01% | +44.4% |
Q2 2016 | $5,571,000 | -44.2% | 239,200 | -3.0% | 0.01% | -43.8% |
Q1 2016 | $9,991,000 | -41.1% | 246,700 | -9.9% | 0.02% | -40.7% |
Q4 2015 | $16,963,000 | – | 273,900 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |